Literature DB >> 3981311

Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. Southwest Pediatric Nephrology Study Group.

.   

Abstract

We describe 11 North American children with hepatitis B-associated membranous glomerulonephropathy (MGN). The children are predominantly black boys (seven of 11) and younger (mean age 5.3 years) than children with idiopathic MGN (10.6 years) or lupus-associated MGN (13.4 years). Most of the patients (10 of 11) had nephrotic syndrome, and although clinical evidence of liver disease was present in only one child, eight of 10 patients had elevated aspartate amino transferase levels. Liver biopsies performed in three children revealed chronic persistent hepatitis in two and chronic active hepatitis in one. Hepatitis B surface antigen was found in the serum of one of the parents of five patients and in the brother of one patient. Low serum C3 values were observed in all 11 children at some stage of their illness. Renal biopsy specimens revealed stage II or III glomerular capillary wall changes, and immunofluorescence studies revealed three or more glomerular immunoreactants in 10 of 11 biopsies. One patient developed end-stage renal disease 9 years after presentation of nephrotic syndrome; the duration of follow-up of the other 10 patients is limited at this time. We conclude from these data that hepatitis B-associated MGN is more frequent in North American children than previous reports have suggested, is most commonly seen in young black boys, and is characterized by low serum C3 levels. It appears, therefore, to be a distinct clinicopathologic entity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981311     DOI: 10.1016/s0022-3476(85)80074-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  Trials and tribulations of multicenter studies. Lessons learned from the experiences of the Southwest Pediatric Nephrology Study Group (SPNSG).

Authors:  R J Hogg
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

Review 2.  Hepatitis B virus. New and evolving issues.

Authors:  B Yoffe; C A Noonan
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

3.  Extrahepatic manifestations of acute hepatitis B virus infection.

Authors:  Matthew R Kappus; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-02

Review 4.  What is the actual management of a child with membranous glomerulopathy associated with chronic hepatitis B?

Authors:  M C Chiu
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

5.  The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication.

Authors:  Lifen Wang; Zhiming Ye; Huaban Liang; Bin Zhang; Lixia Xu; Zhonglin Feng; Shuangxin Liu; Wei Shi
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

6.  Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children.

Authors:  S N Wong; E C Yu; A S Lok; K W Chan; Y L Lau
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

7.  Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation.

Authors:  A Quan; A Portale; S Foster; J Lavine
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

8.  Hereditary partial deficiency of the third component of complement associated with minimal change nephrotic syndrome.

Authors:  J E Springate; R H McLean; J A Winkelstein; L G Feld
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

Review 9.  Viral hepatitis in children with renal disease.

Authors:  G V Gregorio; A P Mowat
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

10.  The clinical course of hepatitis B virus-associated nephropathy.

Authors:  R D Gilbert; J Wiggelinkhuizen
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.